Molecular analysis confirmed IDH1/2-wildtype status, absence of 1p/19q codeletion, and presence of a TERT promoter mutation, consistent with glioblastoma IDH-wildtype per the WHO CNS5 criteria [1]. The gene discussed is IDH1; the disease is glioblastoma.